Skip to content
Screener

10x Genomics, Inc. TXG Spatial — Revenue

Other product segments

Products and services revenue
$149.09M+2.7%
Services
$10.68M+26.0%
Single Cell
$3.09M-46.1%
License and royalty revenue
$1.94M-93.0%

Similar metrics at other companies

TEC
TECHDiagnostics And Spatial Biology — Revenue
$85.59M-4.1%
Pure Cycle logo
PCYOSpecial Facility Projects — Revenue
$200K-11.1%
Metallus logo
MTUSSpecial Bar Quality Bars — Revenue
$200.9M+21.0%
Pure Cycle logo
PCYOSpecial Facility Projects And Other — Revenue
$189K-12.5%
HRO
HROWOther Revenues — Revenue
$73K-15.1%
Oracle logo
ORCLCloud Revenues — Revenue
$9.91B+47.1%

Other financials

Income statement

See full
Revenue$151.0M-12.6%
Gross profit$112.5M-10.1%
Operating income-$19.6M-165%
Net income-$17.9M-152%
EPS (diluted)-$0.14-150%

Balance sheet

See full
Cash & equivalents$502.5M+26.4%
Total debt$78.8M-9.2%
Total equity$825.5M+6.8%
Total assets$1.0B+5.1%

Cash flow

See full
Operating cash flow$17.0M-4.1%
CapEx$1.6M+0.6%
Free cash flow$15.4M-4.6%

Valuation

See full
Market cap$5.79B+271%
Enterprise value$5.37B+330%
P/S9.4×+7.0×

Profitability

See full
Gross margin70%+0.5pp
Operating margin-14.3%-1.1pp
Net margin-12.2%-0.8pp
FCF margin19.7%+10.9pp

Returns & leverage

See full
Return on equity-9.4%-1.4pp
Debt / equity0.1×0.0×
Current ratio5.7×-0.1×

Where this comes from

Reported directly by 10x Genomics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: 10x Genomics, Inc.’s 10-Q, filed August 7, 2026.

Filed
Aug 6, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-054491
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Instruments
Single Cell$3,087$5,727$8,310$11,640
Spatial4,5748,77010,61317,672
Total instruments revenue7,66114,49718,92329,312
Consumables
Single Cell88,45185,788177,345169,897
Spatial42,30136,39783,20867,644
Total consumables revenue130,752122,185260,553237,541

Item 1. Financial Statements (Unaudited)

FAQ

What is 10x Genomics, Inc.'s spatial — revenue?
10x Genomics, Inc. (TXG) reported spatial — revenue of $4.57M in Q2 2026.
How has 10x Genomics, Inc.'s spatial — revenue changed year-over-year?
10x Genomics, Inc.'s spatial — revenue decreased by 47.8% year-over-year, from $8.77M to $4.57M.
What is the long-term trend for 10x Genomics, Inc.'s spatial — revenue?
Over 4 years (2021 to 2025), 10x Genomics, Inc.'s spatial — revenue has grown at a 225.7% compound annual growth rate (CAGR), from $303K to $34.11M.
What does spatial — revenue mean?
This metric represents the total revenue generated specifically from the sale of instruments within the spatial biology product segment. It serves as a key indicator of market adoption for the company's hardware platforms and reflects the initial capital investment made by research institutions and laboratories. Growth in this area typically signals a expanding installed base that will drive future demand for recurring consumable products.

Ask your AI about 10x Genomics, Inc.'s spatial — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude